Nitrogen deletion in the biosynthesis of HDAC-targeting anticancer drugs

Small molecules play indispensable roles in living systems as hormones, membrane bilayer constituents, enzyme cofactors, metal chelators, and defensive chemicals. The exceptional structural diversity of such molecules underpins their wide-ranging biological functions. Precise functional group insertion into various molecular scaffold classes is a hallmark of small molecule biosynthesis and is frequently important for biological activity. Functional group deletion is also important, but mechanisms are less well understood. Here, we report deletion of a cysteine-derived nitrogen atom during assembly of the conserved pharmacophore in the anticancer drug romidepsin, and related depsipeptide HDAC inhibitors. A shunt metabolite hydroxylated at the cysteine--carbon-derived position is a thousand-fold less active, indicating nitrogen deletion is important for potent HDAC inhibition. In vitro reconstitution and dissection of the complete nonribosomal peptide synthetase-polyketide synthase-mediated pathway for pharmacophore assembly reveal that cryptic S-octanoylation is catalysed by an atypical heterocyclisation domain, while multifunctional dehydratase and ketoreductase domains and trans-acting phosphotransferase and flavin-dependent oxidoreductase enzymes catalyse successive transformations in nitrogen deletion. Our findings significantly advance the understanding of heteroatom deletion mechanisms in small molecule biosynthesis and highlight the key role this can play in enhancing bioactivity. One-pot biocatalytic synthesis of the pharmacophore provides foundations for chemoenzymatic approaches to next-generation HDAC inhibitors.